Highlights
- TGen researchers used a new viral delivery system to study amyloid, tau, and alpha-synuclein proteins together in a single mouse model.
- Alpha-synuclein and tau introduced after amyloid plaque formation increased toxic protein aggregations and worsened anxiety and hyperactivity behaviors in mice.
- Tau pathology alone triggered a hyper-inflammatory response in white matter tracts, a finding researchers say warrants closer examination in human brains.
- Next steps include testing the mouse model against recently approved Alzheimer's treatments, according to senior author John Fryer, Ph.D.
A TGen research team has published findings that clarify how three dementia-linked proteins, amyloid-beta, tau, and alpha-synuclein, interact in the brain, with implications for how future combination therapies might be designed.
The study, published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, used a mouse model that allows researchers to introduce different mixtures of the proteins at different stages of disease progression. Benjamin Rabichow, Ph.D., a former graduate student who is now a postdoctoral fellow in pathology at the University of California, San Diego, served as first author. John Fryer, Ph.D., inaugural director of TGen's Center for Accelerated Nanotherapeutics, was senior author.
The central finding: timing matters. When alpha-synuclein and tau were introduced into mice after amyloid plaques had already formed, the proteins reached higher levels of toxic aggregation and produced more pronounced anxiety and hyperactivity behaviors than in mice where the proteins were introduced before plaque deposition. Mice in the pre-plaque group still developed pathological protein levels and mild behavioral symptoms, but at a slower rate.
Rabichow offered one possible explanation: amyloid may compromise the cellular machinery the brain uses to clear additional pathological proteins, leaving it less equipped to handle the added burden.
A separate finding drew attention to white matter. Tau pathology alone, independent of the other proteins, produced a hyper-inflammatory response in non-neuronal cells in certain white matter tracts, regions clinicians do not routinely examine when screening for Alzheimer's markers. The researchers say that gap may be worth closing.
TGen is part of City of Hope and is based in Phoenix. The next phase of the research will test the mouse model against recently approved Alzheimer's treatments, according to Fryer.
Sources
Every factual claim in this article traces to one of the sources below. See how we work for the editorial process.
- tgen.org retrieved 09/07/2026 04:05
Authored by The Scottsdale Signal. Drafted by AI from primary-source material under our beat-specific editorial guides; reviewed by humans before publish under our five-gate process. Sources retrieved at 09/07/2026 04:05. Every claim traces to a source.
